Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Running, not enrolling · Phase 2

Conditions studied: Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma

In brief

This pilot phase II trial studies how well giving brentuximab vedotin, combination chemotherapy, and radiation therapy works in treating younger patients with stage IIB, IIIB or IV Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer killing substances to them. Drugs used in chemotherapy, such as etoposide, prednisone, doxorubicin hydrochloride, cyclophosphamide, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving brentuximab vedotin with combination chemotherapy may kill more cancer cells and reduce the need for radiation therapy.

Key facts

Study ID

NCT01920932

Run by

St. Jude Children's Research Hospital

People needed

77

Starts

2013-08-12

Expected to finish

2028-05-01

Last updated by the study team

2026-05-06

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed, previously untreated CD30+ classical Hodgkin Lymphoma (HL). (Participants receiving limited emergent radiation therapy (RT) or steroid therapy - maximum of 7 days - because of cardiopulmonary decompensation or spinal cord compression will be eligible for protocol enrollment).
• Age ≤ 18 years at the time of diagnosis (i.e., participants are eligible until their 19th birthday).
• Ann Arbor stage IIB, IIIB, IVA, or IVB.
• Adequate renal function based on GFR ≥ 70 ml/min/1.73m\^2 or serum creatinine adjusted for age and gender.
• Adequate hepatic function (total bilirubin < 1.5 x ULN for age, and SGOT/SGPT < 2.5 x ULN for age).
• Female participant who is post-menarchal must have a negative urine or serum pregnancy test.
• Female or male participant of reproductive potential must agree to use an effective contraceptive method throughout duration of study treatment.

You may not qualify if…

• CD30 negative HL.
• Has received prior therapy for Hodgkin lymphoma, except as noted above.
• Inadequate organ function as described above.
• Inability or unwillingness of research participant or legal guardian / representative to give written informed consent.

Where it is running

• Lucile Packard Children's Hospital Stanford University — Palo Alto, California, United States
• St. Jude Midwest Affiliate — Peoria, Illinois, United States
• Maine Children's Cancer Program (MCCP) — Scarborough, Maine, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Dana-Farber Harvard Cancer Center — Boston, Massachusetts, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.